New glucose monitor aims for pinpoint accuracy in diabetes care
NCT ID NCT07679347
First seen Jul 01, 2026 · Last updated Jul 08, 2026 · Updated 3 times
Summary
This pilot study tests a new continuous glucose monitor (CGM) called SAVA in 20 adults with Type 1 Diabetes. Participants wear three SAVA sensors and one standard sensor for 15 days to check how well the SAVA measures blood sugar compared to lab tests. The study also looks at comfort and safety. Results will help decide if larger studies are worthwhile.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SAVA Continuous Glucose Monitor (device)
- What this could lead to
- If successful, this could lead to a more accurate and comfortable glucose monitor for people with Type 1 Diabetes.
- What could go wrong
- This is a small pilot study with only 20 participants, so results may not apply to everyone. The device may not meet accuracy targets or may cause discomfort.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a smart pen take the guesswork out of insulin dosing?
- AI takes the wheel: could a smart algorithm optimize insulin pumps from home?
- Can a common diabetes pill make insulin therapy safer and more effective for type 1 diabetes?
- Real-World test of automated insulin system aims to improve blood sugar control for type 1 diabetes
- Can a wearable sensor help young people with type 1 diabetes tame blood sugar swings?
- Can a smartphone app help teens tame type 1 diabetes?